Watch PLYX. Know when insiders buy.
One email the day a filing lands. Free.
PLYX
Polaryx Therapeutics, Inc.
2.09
−0.05 −2.34%
USD · close Sep 25
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
100
PASS · shorts 100
Insiders, 90 days
0
no open-market filings in 90 days
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $104.2MP/E —DIV YIELD —FCF YIELD —REV TTM —NET INCOME −$9MNET CASH —52W 1.87 – 35.00SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | — | — | — | −$1.4M | −$1.4M | — | -0.03 | −$1.4M | — | — | Aug 13 |
| Q1 2026 · Mar 31 | — | — | — | −$2M | −$2.5M | — | -0.05 | −$2.1M | — | — | May 15 |
| Q2 2025 · Jun 30 | — | — | — | −$884K | −$1M | — | -0.02 | −$858K | — | — | Aug 13 |
| Q1 2025 · Mar 31 | — | — | — | −$5.1M | −$5.1M | — | -0.11 | −$709K | — | — | May 15 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | — | — | −$7.8M | −$9M | — | -0.20 | −$3.9M | — | — | — | — |
| FY2024 · to Dec 31 | — | — | −$4.4M | −$30.4M | — | -0.89 | −$2.6M | — | — | — | — |
Every number comes from Polaryx Therapeutics, Inc.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.